August 14, 2025

Meeting Slides: https://t1dx-qi.t1dexchange.org/wp-content/uploads/2025/08/DSC-Aug-2025.pdf

Attendees:  Ryan McDonough, Nirali Shah, Todd Alonso, Meenal Gupta, Jenise Wong, Candice Williams, Andrew Lavik, Emma Ospelt, Susan Thapa, Saketh Rompicherla, James Dawson, Dhruvi Vora

Agenda:

• Introductions- Ryan McDonough and Nirali Shah
• T1D Exchange Updates- Emma, T1D Exchange
• Q4 DSC meeting-last of the year -Emma, T1D Exchange
• Creating a T1DX-QI Data Mapping Guideline- James, T1D Exchange
• Improving care for T2D and nephropathy- Dr. Nirali Shah
• Remote Monitoring Data- Dr. Ryan McDonough

Type 1 Diabetes Mapping Updates

• 46 centers fully mapped
• 6 in validation phase

Type 2 Diabetes Mapping Update

• 5 centers in production
• 3 centers still in the mapping process

T1DX-QI Scorecards

• Currently in production and will be sent out by the end of September to mapped centers
• In the future we will be sharing these annually

Creating a Data Mapping Guideline

• 2-3 page guide for clinics to help them have an SOP so that if there are staffing changes, people know how to do essential things
• What would new people have to know to do the next data pull or make a modification?
• James shared draft document and will be adding in some plainer language and definitions and will share final draft

“FINER Care” Optimizing Care for Diabetic Nephropathy: A Quality Improvement Initiative with Finerenone Presentation

• Overview of project and will be rolling out an OPA (Our Practice Advisory) for Finerenone in patients with type 2 diabetes among other inclusion and exclusion criteria
• Will plan to share updates once the OPA is rolled out-possibly to expand collaborative wide
• Share feedback with current BPA project in collaborative

Remote Monitoring Data

• Possibly a new area to collect data-how do we collect this?
  • Collecting alerts in the background of how often devices are used/altered to
  • How frequently patients are opening their diabetes related apps
  • Does this lead to increased burden?
  • Challenges exist to this data collection and quantifying these definitions
• How can we evaluate if this non-stop availability poses possible negative impact to the patient/parent wellness or patient glycemic control ?
• Goal: to quantify the amount of time parents/patients spend observing their glucose data, and to evaluate if this non-stop availability poses possible negative impact to the patient/parent wellness or patient glycemic control
• Possible starting point– quantitatively evaluate the impact of time spent in remote monitoring apps on parental wellness, patient self-efficacy, and glycemic outcomes in youth and adolescents with T1D
• Additionally, would be interesting relating to camp as well and parental control/breaks from phone

Future meeting discussions: the use of AI scribe and capturing this unstructured data            

Next meeting:  aiming for first week in December –2pm EST

Updates to be shared via email